Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumors – A pooled analysis of five clinical trials

#3795

Introduction: There is an increasing interest in the role of sex and gender in cancer patients. The impact of sex differences in systemic oncological therapies is still unknown, and there is a lack of evidence, especially in uncommon neoplasms like neuroendocrine tumors (NET).

Aim(s): In the present study, we combine the differential drug-related toxicities by sex in five published clinical trials with tyrosine kinase inhibitors (TKI) in gastroenteropancreatic (GEP) NET.

Materials and methods: A pooled analysis was performed with patients treated with sunitinib, pazopanib, lenvatinib, or sorafenib-bevacizumab in five multicenter open-label phase 2 and 3 trials: SU11248, SUN1111, GETNE0801, PAZONET, and TALENT.

Conference:

Presenting Author:

Authors: Hernando Cubero J, Roca-Herrera M, Garcia Alvarez A, Raymond E, Kulke M,

Keywords: Sex, Toxicity, Tyrosine Kinase Inhibitor,